Skip to content

Chronic Lung Allograft Dysfunction MRI Study

Validation of MRI, CT and Pulmonary Function Tests for Early Detection of Chronic Lung Allograft Dysfunction

Status
Recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06406777
Enrollment
100
Registered
2024-05-09
Start date
2025-03-20
Completion date
2028-09-01
Last updated
2026-08-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Lung Allograft Dysfunction Lung MRI (CLAD)

Keywords

Lung Transplant

Brief summary

This studies purpose is to confirm the efficacy and efficiency of using OE-MRI and MRI with hyperpolarized gas techniques and Iodinated contrast CT scan, this will enhance understanding of CLAD pathophysiology. Moreover, this project is foundational to performing additional studies to establish if novel MRI imaging can serve as an objective confirmatory diagnostic tool for CLAD in post-transplant patients.

Detailed description

This studies purpose is to confirm the efficacy and efficiency of using OE-MRI and MRI with hyperpolarized gas techniques and Iodinated contrast CT scan, this will enhance understanding of CLAD pathophysiology. Moreover, this project is foundational to performing additional studies to establish if novel MRI imaging can serve as an objective confirmatory diagnostic tool for CLAD in post-transplant patients. This observational imaging study will use 3T UTE MRI with varying oxygen levels (room air vs. 100% oxygen) to evaluate lung ventilation using oxygen enhanced imaging, in 50 healthy normal subjects (age 18-80). Subjects will have vital signs taken, complete questionnaires and have pulmonary function test (spirometry) done, Iodinated contrast CT scan and standard of care CT scans, in addition to one MRI session that will include 6 series of scans. The MRI scans will be taken in supine position (laying on back) and include breathing room air and 100% oxygen. OE-MRI will be done in addition to MRI scans with Xenon-129.

Interventions

DIAGNOSTIC_TESTSpirometry

Spirometry measures lung function, specifically the amount and/or speed of air that can be inhaled and exhaled.

DIAGNOSTIC_TESTContrast Lung Computed Tomography (CT) Scan

CT scan of the lungs using contrast

DIAGNOSTIC_TESTOxygen enhanced magnetic resonance imaging (OE-MRI) Scan

MRI will be taken while subject is lying on their back breathing 100% oxygen.

DRUG129Xe MRI scans

MRI will be taken while subject is lying on their back breathing room oxygen and taking a breath of 129Xe and holding it for a few seconds.

Sponsors

Sean Fain
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Intervention model description

Three populations that will all have the same interventions.

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

All subjects-Inclusion Criteria: * Ages 18-80 * English Speaking Subjects * Willingness and ability to provide informed consent * Non-smoker Lung transplant patients-inclusion criteria: * \>/= 6 months from lung transplant * History of bilateral lung transplant CLAD-free patients-inclusion criteria: * Stable spirometry with FEV1 \> 90% of baseline value (average of 2 best values) and forced mid-expiratory flow (FEF) (25-75) \> 75% of baseline * Total Lung Capacity (TLC) \> 90 % of baseline * Post-transplant chest radiograph without significant abnormality * No evidence of on-going lung infection or allograft rejection Early CLAD patients-inclusion criteria: * FEV1 \< 80% of baseline value (average of 2 best values) * Follow up 6-months or decline in lung function (20% decrease in FEV1 without evidence of infection or acute rejection)

Exclusion criteria

* SAO2 drops below 90% (in absence of mechanical failure) during normal tidal breathing * Unilateral diaphragm paralysis * Evidence of acute illness on day of study * Evidence of restrictive lung disease * Dependence on supplemental oxygen * History of cardiac disease * Pregnancy (self-declared) * Lactating women * Participants with metal objects in their body * Known contraindication to MRI examination * Systolic blood pressure reading of \< 100 mmHg or \> 200 mmHg * Diastolic blood pressure reading of \<60 mmHg or \> 100 mmHg

Design outcomes

Primary

MeasureTime frameDescription
Forced expiratory volume in 1 second (FEV1) DeclineBaseline and 3 monthsAbsolute decrease of FEV1 by 20%

Countries

United States

Contacts

CONTACTSean Fain, Ph.D.
sean-fain@uiowa.edu319 356 4832
PRINCIPAL_INVESTIGATORSean Fain, Ph.D

University of Iowa

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 7, 2026